BTK and B-cell chronic lymphocytic leukemia: By inhibiting BTK, ibrutinib prevents re-expression of sufficient levels of functional surface membrane chemokine receptors (e.g. CXCR4) and thereby causes failure of CLL B cells to re-enter niches, leading to greater cell death and delay in CLL disease progression [4, 5].